Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
ID: 345272Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $250K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345272

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral measures in animal models to enhance the early-phase therapeutic development for mental illnesses, addressing the challenges faced in novel treatment development over the past two decades. Successful applications must focus on optimizing these measures to reflect human assays, validating their sensitivity and selectivity through pharmacodynamic studies, and ensuring they are clinically relevant. The grant has an award ceiling of $250,000, with applications accepted until September 7, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-091-Full-Announcement.html
    PAR-23-091.html
    The Department of Health and Human Services, via the National Institutes of Health (NIH), has launched a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral measures in animals to enhance early-phase therapeutic development for mental illnesses. Recognizing the limited success in novel treatment development over the past two decades, this FOA seeks to identify biomarkers reflective of neural processes associated with mental health conditions. Successful applications must optimize these measures to mirror human assays, assess their sensitivity and selectivity through pharmacodynamic studies, and validate the underlying brain processes influencing behavior. Eligible applicants include academic institutions, nonprofits, and for-profit entities, with an open application period running until September 2025. Significantly, this opportunity discourages the use of human subjects and emphasizes the creation of clinically relevant, translational assays in animal models, contributing significantly to mental health research and therapeutic development pipelines.
    Similar Opportunities
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development," aimed at developing neurophysiological assays to enhance treatment strategies for mental disorders. This initiative seeks to support partnerships among neuroscientists to optimize and evaluate pharmacodynamic measures in both human subjects and relevant animal models, thereby improving the efficiency of preclinical and clinical trials. The UG3/UH3 cooperative agreement format will facilitate a two-phase approach, focusing first on feasibility and assay optimization, followed by comparative performance evaluations. Interested applicants can find more information and submit proposals by June 20, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)" aimed at supporting research into the connections between brain circuit maturation and behavioral development in rodents and non-human primates. This initiative seeks to explore how neural interactions evolve during pre- and post-natal development, influencing cognitive, emotional, and social behaviors, with a focus on in vivo neural measures and developmental trajectories from prenatal stages to early adulthood. Grants of up to $500,000 per year are available for a maximum duration of five years, with applications due by January 7, 2025. Interested applicants can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and detailed guidelines are available at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-066.html.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research in drug discovery for psychiatric disorders. The initiative focuses on the development and validation of screening assays to identify effective chemical hits for conditions such as depression, bipolar disorder, and schizophrenia, encouraging innovative approaches in mental health research. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions and community-based organizations, with no budget limits and a maximum project period of five years. Interested parties can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications accepted until May 7, 2026.
    Basic Neurodevelopmental Biology of Circuits and Behavior (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Basic Neurodevelopmental Biology of Circuits and Behavior (R21 Clinical Trial Not Allowed)," aimed at supporting research projects that investigate the connections between brain circuit maturation and behavioral development in rodents and non-human primates. The initiative seeks to enhance understanding of how brain region interactions evolve during pre- and postnatal development, particularly in relation to cognitive, affective, and social behaviors, while employing innovative methodologies and in vivo neural measures in awake animals. With a funding ceiling of $275,000 over a two-year period, the application deadline is set for January 7, 2025. Interested applicants can find more information and guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders" (FOA Number PAR-23-093). This grant aims to promote research focused on invasive neural recording studies that explore the neural circuitry underlying mental health disorders, with an emphasis on high translational potential in understanding moods, cognitive functions, and behaviors. The initiative encourages collaboration among diverse research teams in fields such as neurosurgery, electrophysiology, and psychology, while specifically excluding general neuroscience studies that do not focus on mental health or intervention development. Interested applicants can submit proposals until January 7, 2025, with no specific budget limits for projects that may extend up to five years; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-093.html.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)." This funding initiative aims to support invasive neural recording studies that address mental health-related questions, focusing on understanding the neural circuitry and dynamics underlying complex behaviors, emotions, and cognitive functions. The R21 grant mechanism encourages innovative, short-term research proposals with a budget of up to $275,000 over two years, while emphasizing the importance of diverse research teams from various clinical fields. Interested applicants should note that the application deadline is January 7, 2025, and can find further details and guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This grant supports projects that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices, focusing on improving spatial and temporal precision and enabling multi-focal approaches for effective treatment delivery. The initiative is crucial for addressing clinical limitations in mental health technologies and encourages collaboration among multidisciplinary teams with expertise in neuroscience, engineering, and regulatory affairs. Interested applicants can apply for up to $275,000 over a two-year project period, with applications due by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-038.html.
    Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required). This initiative aims to support innovative clinical trials that investigate novel interventions for mental health conditions, including schizophrenia, depression, and anxiety, with a focus on establishing proof of mechanism and target engagement in the R61 phase and confirming findings on a larger scale in the R33 phase. The total funding commitment for this initiative is $27 million for FY 2022, and eligible applicants include a diverse range of entities such as higher education institutions, nonprofits, and various government organizations, both domestic and foreign. Interested parties should note that the application deadline is October 15, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at funding research for assay development and neurotherapeutic agent identification for neurological disorders. This grant opportunity encourages the creation of in vitro and ex vivo assays and iterative screening to identify potential therapeutic agents, with a focus on projects that can transition to the Blueprint Neurotherapeutics Network. The initiative is particularly significant for advancing therapeutic options for underserved populations, with a funding limit of $499,000 per year and a total maximum of $750,000 over three years, while excluding any clinical trial-related research. Interested applicants can find more information and contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV, with applications due by October 21, 2024.